<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 14_6 - Prostate Cancer</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 14_6 - Prostate Cancer | MD3 SCP Cases">
  <meta name="description" content="Medical case study for MD3 students.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 14_6 - Prostate Cancer">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Medical case study for MD3 students.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 14.6 – Prostate Cancer</h1>
    <p class="meta"><strong>Category:</strong> Renal and Urinary Systems | <strong>Discipline:</strong> Medicine - Urology | <strong>Setting:</strong> Urban General Practice</p>

    <h2>Case</h2>
    <p>Harold Lynch, 68 year old retired bank manager, presents for his six monthly check-up.</p>
    <p>He has been feeling very well in himself lately and has no specific complaints today. He asks about getting a blood test done to check his "prostate", because a friend of his was recently diagnosed with prostate cancer.</p>

    <h2>Questions</h2>

    <div class="question">
      <strong>1. What are the key points on history and examination that you would carry out, in view of his concerns about prostate cancer?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>History</strong></p>
        <ul>
          <li>Age (prostate cancer is predominantly a disease of the elderly, over 50's. Younger men rarely get prostate cancer)</li>
          <li>Family history of prostate cancer (first degree relative with disease or family history of breast cancer)</li>
          <li>Past medical history: UTI</li>
          <li>Symptoms of benign prostatic hypertrophy (BPH): hesitancy, frequency, urgency, nocturia, poor stream, terminal dribbling, sensation of incomplete emptying</li>
          <li>Haematuria</li>
          <li>Symptoms that may suggest advanced disease: weight loss, bone pain (back pain), symptoms of anaemia</li>
        </ul>
        <p><strong>Examination</strong></p>
        <ul>
          <li>General examination: pallor, cachexia</li>
          <li>Abdominal examination: palpable bladder, masses, lymphadenopathy</li>
          <li>Digital rectal examination (DRE): assess prostate size, consistency, symmetry, nodules, tenderness
            <ul>
              <li>Normal prostate: smooth, symmetrical, firm, non-tender, about 3cm in diameter</li>
              <li>BPH: enlarged, smooth, symmetrical, firm/rubbery</li>
              <li>Prostate cancer: hard, irregular, asymmetrical, may have palpable nodules</li>
              <li>Prostatitis: tender, boggy</li>
            </ul>
          </li>
          <li>Neurological examination of lower limbs if symptoms suggest spinal cord compression</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>2. What is the role of PSA testing in the detection of prostate cancer?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <ul>
          <li>PSA (Prostate Specific Antigen) is a glycoprotein enzyme produced by the prostate gland</li>
          <li>PSA is organ-specific but not cancer-specific – can be elevated in BPH, prostatitis, UTI, after instrumentation or DRE, and in prostate cancer</li>
          <li>PSA levels increase with age – age-specific reference ranges should be used</li>
          <li>Normal PSA: generally &lt;4 ng/mL, but this varies with age:
            <ul>
              <li>40-49 years: &lt;2.5 ng/mL</li>
              <li>50-59 years: &lt;3.5 ng/mL</li>
              <li>60-69 years: &lt;4.5 ng/mL</li>
              <li>70-79 years: &lt;6.5 ng/mL</li>
            </ul>
          </li>
          <li>PSA >10 ng/mL is associated with significantly increased risk of prostate cancer</li>
          <li>PSA is not recommended as a screening test for prostate cancer in asymptomatic men (controversial):
            <ul>
              <li>Low specificity – many false positives (elevated PSA without cancer)</li>
              <li>PSA screening may lead to detection of clinically insignificant cancers (overdiagnosis)</li>
              <li>No clear evidence that PSA screening reduces mortality from prostate cancer</li>
              <li>Potential harms: anxiety, unnecessary biopsies, overtreatment of indolent cancers</li>
            </ul>
          </li>
          <li>PSA testing may be offered to men >50 years (\&gt;45 if African ancestry or family history) who request it after informed discussion of risks and benefits</li>
          <li>PSA is useful for:
            <ul>
              <li>Assessment of men with symptoms suggestive of prostate cancer</li>
              <li>Monitoring response to treatment in men with diagnosed prostate cancer</li>
              <li>Detecting recurrence after treatment</li>
            </ul>
          </li>
          <li>PSA velocity (rate of change over time) may be more useful than single values</li>
          <li>Free PSA:total PSA ratio may help distinguish BPH from cancer (lower ratio suggests cancer)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>3. Outline the epidemiology and aetiology of prostate cancer.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Epidemiology</strong></p>
        <ul>
          <li>Most common cancer in men in Ireland and UK</li>
          <li>Second most common cause of cancer death in men (after lung cancer)</li>
          <li>Incidence increases with age – rare under 50, most cases occur in men >65 years</li>
          <li>Lifetime risk approximately 1 in 8 men</li>
          <li>Geographical variation: highest rates in Western countries, lowest in Asia</li>
          <li>Incidence has increased due to PSA testing and ageing population</li>
          <li>Mortality has decreased due to earlier detection and improved treatments</li>
          <li>Many prostate cancers are slow-growing and may not cause problems during a man's lifetime (indolent disease)</li>
        </ul>
        <p><strong>Aetiology and risk factors</strong></p>
        <ul>
          <li><strong>Age:</strong> strongest risk factor – incidence increases markedly after 50</li>
          <li><strong>Family history:</strong> 2-3 fold increased risk if first-degree relative affected. Risk increases with number of affected relatives and younger age at diagnosis. Hereditary prostate cancer accounts for 5-10% of cases</li>
          <li><strong>Ethnicity:</strong> highest incidence in African-Caribbean men, lowest in Asian men</li>
          <li><strong>Genetic factors:</strong> mutations in BRCA1 and BRCA2 genes increase risk</li>
          <li><strong>Hormonal factors:</strong> androgens (testosterone) are required for prostate cancer development and growth</li>
          <li><strong>Dietary factors:</strong> high fat diet, low fruit and vegetable intake may increase risk (weak evidence). Obesity may be associated with more aggressive disease</li>
          <li><strong>Environmental factors:</strong> occupational exposure to cadmium, pesticides (weak evidence)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>4. Describe the pathology of prostate cancer.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <ul>
          <li><strong>Histology:</strong> 95% are adenocarcinomas arising from the peripheral zone of the prostate (70% peripheral zone, 20% transition zone, 10% central zone)</li>
          <li><strong>Grading – Gleason score:</strong>
            <ul>
              <li>Based on histological pattern/architecture of the tumour</li>
              <li>Graded from 1 (well-differentiated) to 5 (poorly differentiated)</li>
              <li>Two most common patterns are added together to give Gleason score (range 2-10)</li>
              <li>Gleason score 6 (3+3): low grade, well-differentiated</li>
              <li>Gleason score 7 (3+4 or 4+3): intermediate grade</li>
              <li>Gleason score 8-10: high grade, poorly differentiated</li>
              <li>Higher Gleason scores associated with more aggressive disease and poorer prognosis</li>
            </ul>
          </li>
          <li><strong>Spread:</strong>
            <ul>
              <li>Local invasion: through prostatic capsule to seminal vesicles, bladder neck, rectum</li>
              <li>Lymphatic spread: to pelvic and para-aortic lymph nodes</li>
              <li>Haematogenous spread: to bone (osteoblastic metastases – most common site), lung, liver</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>5. What are the clinical presentations of prostate cancer?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <ul>
          <li><strong>Asymptomatic:</strong> detected by elevated PSA or abnormal DRE in asymptomatic men</li>
          <li><strong>Lower urinary tract symptoms (LUTS):</strong> 
            <ul>
              <li>Hesitancy, weak stream, frequency, urgency, nocturia</li>
              <li>Usually due to coexistent BPH rather than cancer itself</li>
              <li>Cancer in peripheral zone less likely to cause LUTS until advanced</li>
            </ul>
          </li>
          <li><strong>Haematuria or haematospermia</strong></li>
          <li><strong>Symptoms of locally advanced disease:</strong>
            <ul>
              <li>Acute urinary retention</li>
              <li>Pelvic pain, perineal pain</li>
              <li>Erectile dysfunction</li>
              <li>Rectal symptoms (tenesmus, bleeding) – rare</li>
              <li>Hydronephrosis (due to ureteric obstruction) – loin pain, renal failure</li>
            </ul>
          </li>
          <li><strong>Symptoms of metastatic disease:</strong>
            <ul>
              <li>Bone pain (especially back pain from vertebral metastases) – most common presentation of metastatic disease</li>
              <li>Pathological fractures</li>
              <li>Spinal cord compression – back pain, leg weakness, sensory loss, urinary retention, faecal incontinence (urological emergency)</li>
              <li>Weight loss, fatigue, anaemia</li>
              <li>Lymphoedema (due to lymph node involvement)</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>6. How would you investigate a patient with suspected prostate cancer?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <ul>
          <li><strong>Serum PSA:</strong> elevated in majority of cases, but can be normal</li>
          <li><strong>Digital rectal examination (DRE):</strong> palpable abnormality in ~50% of cases</li>
          <li><strong>Transrectal ultrasound (TRUS) guided biopsy:</strong>
            <ul>
              <li>Definitive diagnostic test</li>
              <li>Multiple cores (10-12) taken from different areas of prostate</li>
              <li>Provides histological diagnosis and Gleason score</li>
              <li>Complications: bleeding (haematuria, haematospermia, rectal bleeding), infection (sepsis), urinary retention</li>
            </ul>
          </li>
          <li><strong>Multiparametric MRI prostate:</strong>
            <ul>
              <li>Increasingly used before biopsy to identify suspicious areas</li>
              <li>Can help target biopsies (MRI-fusion biopsy)</li>
              <li>May reduce unnecessary biopsies in men with low-risk abnormalities</li>
            </ul>
          </li>
          <li><strong>Staging investigations (if cancer confirmed):</strong>
            <ul>
              <li>Bone scan: to detect bone metastases (if PSA >10, high Gleason score, or bone pain)</li>
              <li>CT or MRI pelvis: to assess local extent and lymph node involvement</li>
              <li>Chest X-ray or CT chest: if suspicion of lung metastases</li>
            </ul>
          </li>
          <li><strong>Other investigations:</strong>
            <ul>
              <li>FBC: anaemia (chronic disease, bone marrow infiltration)</li>
              <li>Renal function: obstructive uropathy</li>
              <li>Liver function tests</li>
              <li>Bone profile: alkaline phosphatase (elevated in bone metastases), calcium</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>7. Describe the staging classification and risk stratification for prostate cancer.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>TNM staging</strong></p>
        <ul>
          <li><strong>T (Tumour):</strong>
            <ul>
              <li>T1: Clinically inapparent tumour (not palpable or visible on imaging)
                <ul>
                  <li>T1a: ≤5% of resected tissue (incidental finding at TURP)</li>
                  <li>T1b: >5% of resected tissue</li>
                  <li>T1c: Tumour identified by needle biopsy (e.g. elevated PSA)</li>
                </ul>
              </li>
              <li>T2: Tumour confined within prostate
                <ul>
                  <li>T2a: Involves ≤50% of one lobe</li>
                  <li>T2b: Involves >50% of one lobe</li>
                  <li>T2c: Involves both lobes</li>
                </ul>
              </li>
              <li>T3: Tumour extends through prostatic capsule
                <ul>
                  <li>T3a: Extracapsular extension</li>
                  <li>T3b: Invades seminal vesicles</li>
                </ul>
              </li>
              <li>T4: Tumour invades adjacent structures (bladder neck, rectum, pelvic wall)</li>
            </ul>
          </li>
          <li><strong>N (Nodes):</strong>
            <ul>
              <li>N0: No regional lymph node metastases</li>
              <li>N1: Regional lymph node metastases</li>
            </ul>
          </li>
          <li><strong>M (Metastases):</strong>
            <ul>
              <li>M0: No distant metastases</li>
              <li>M1: Distant metastases
                <ul>
                  <li>M1a: Non-regional lymph nodes</li>
                  <li>M1b: Bone</li>
                  <li>M1c: Other sites</li>
                </ul>
              </li>
            </ul>
          </li>
        </ul>
        <p><strong>Risk stratification (for localized disease)</strong></p>
        <p>Based on PSA, Gleason score, and clinical stage:</p>
        <ul>
          <li><strong>Low risk:</strong> PSA &lt;10, Gleason ≤6, stage T1-T2a</li>
          <li><strong>Intermediate risk:</strong> PSA 10-20, or Gleason 7, or stage T2b</li>
          <li><strong>High risk:</strong> PSA >20, or Gleason 8-10, or stage T2c-T3</li>
        </ul>
        <p>Risk stratification helps guide treatment decisions and predict prognosis</p>
      </div>
    </div>

    <div class="question">
      <strong>8. Outline the treatment options for prostate cancer.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Treatment depends on stage, grade, patient age, comorbidities and patient preference</p>
        <p><strong>Localized disease (T1-T2, N0, M0)</strong></p>
        <ul>
          <li><strong>Active surveillance:</strong>
            <ul>
              <li>Appropriate for low-risk, slow-growing cancers</li>
              <li>Regular monitoring with PSA, DRE, repeat biopsies</li>
              <li>Treatment initiated if disease progresses</li>
              <li>Avoids side effects of treatment for indolent cancers</li>
              <li>Suitable for elderly men with limited life expectancy or significant comorbidities</li>
            </ul>
          </li>
          <li><strong>Radical prostatectomy:</strong>
            <ul>
              <li>Surgical removal of entire prostate and seminal vesicles</li>
              <li>Can be open, laparoscopic, or robotic-assisted</li>
              <li>Curative intent for localized disease</li>
              <li>Side effects: erectile dysfunction (30-70%), urinary incontinence (5-20%), risk of anastomotic stricture</li>
              <li>PSA should become undetectable after surgery</li>
            </ul>
          </li>
          <li><strong>External beam radiotherapy (EBRT):</strong>
            <ul>
              <li>Curative intent for localized disease</li>
              <li>Typically 7-8 weeks of daily treatment</li>
              <li>Side effects: urinary symptoms (frequency, urgency), bowel symptoms (diarrhoea, rectal bleeding), erectile dysfunction (develops gradually over months-years)</li>
              <li>Can be combined with androgen deprivation therapy (ADT) for higher-risk disease</li>
            </ul>
          </li>
          <li><strong>Brachytherapy:</strong>
            <ul>
              <li>Radioactive seeds implanted directly into prostate</li>
              <li>Low dose rate (LDR) – permanent seeds</li>
              <li>High dose rate (HDR) – temporary implants</li>
              <li>Can be used alone or in combination with EBRT</li>
              <li>Suitable for low-intermediate risk disease</li>
            </ul>
          </li>
        </ul>
        <p><strong>Locally advanced disease (T3-T4)</strong></p>
        <ul>
          <li>Radiotherapy (EBRT) + androgen deprivation therapy (ADT) for 2-3 years</li>
          <li>Radical prostatectomy may be considered in selected cases</li>
        </ul>
        <p><strong>Metastatic disease (N1 or M1)</strong></p>
        <ul>
          <li><strong>Androgen deprivation therapy (ADT):</strong>
            <ul>
              <li>Mainstay of treatment for metastatic disease</li>
              <li>Prostate cancer is androgen-dependent</li>
              <li>Methods:
                <ul>
                  <li>LHRH agonists (goserelin, leuprorelin) – cause initial testosterone surge then suppression</li>
                  <li>LHRH antagonists (degarelix) – immediate testosterone suppression, no surge</li>
                  <li>Anti-androgens (bicalutamide, enzalutamide)</li>
                  <li>Bilateral orchidectomy (surgical castration) – rarely used now</li>
                </ul>
              </li>
              <li>Side effects: hot flushes, loss of libido, erectile dysfunction, fatigue, osteoporosis, weight gain, gynaecomastia, anaemia, increased cardiovascular risk</li>
              <li>Most patients initially respond well (months-years)</li>
              <li>Eventually disease becomes castration-resistant (CRPC)</li>
            </ul>
          </li>
          <li><strong>Chemotherapy:</strong>
            <ul>
              <li>Docetaxel – first-line for metastatic CRPC</li>
              <li>Cabazitaxel – second-line</li>
              <li>May be combined with ADT in newly diagnosed high-volume metastatic disease</li>
            </ul>
          </li>
          <li><strong>Novel hormonal agents for CRPC:</strong>
            <ul>
              <li>Abiraterone (CYP17 inhibitor – blocks androgen synthesis)</li>
              <li>Enzalutamide (androgen receptor antagonist)</li>
            </ul>
          </li>
          <li><strong>Radium-223:</strong>
            <ul>
              <li>Targeted alpha therapy for bone metastases</li>
              <li>Improves survival and reduces skeletal events in CRPC with bone metastases</li>
            </ul>
          </li>
          <li><strong>Bisphosphonates or denosumab:</strong>
            <ul>
              <li>Reduce skeletal-related events in bone metastases</li>
              <li>Treatment of osteoporosis in men on ADT</li>
            </ul>
          </li>
          <li><strong>Palliative radiotherapy:</strong>
            <ul>
              <li>For painful bone metastases</li>
              <li>For spinal cord compression</li>
            </ul>
          </li>
        </ul>
        <p><strong>Emergency treatments</strong></p>
        <ul>
          <li><strong>Spinal cord compression:</strong> High-dose dexamethasone + urgent radiotherapy or surgical decompression</li>
          <li><strong>Acute urinary retention:</strong> Catheterization, TURP if persistent, ADT may help</li>
        </ul>
        <p><strong>Prognosis</strong></p>
        <ul>
          <li>Overall 5-year survival >90%</li>
          <li>Localized disease: 5-year survival ~100%</li>
          <li>Locally advanced: 5-year survival ~95%</li>
          <li>Metastatic disease: 5-year survival ~30%</li>
          <li>Many men with prostate cancer die with the disease rather than from it</li>
        </ul>
      </div>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>